期刊文献+

小檗碱对大鼠骨髓源性破骨细胞的分化及骨吸收功能的影响(英文) 被引量:14

Effects of berberine on differentiation and bone resorption of osteoclasts derived from rat bone marrow cells
下载PDF
导出
摘要 目的:研究小檗碱对破骨细胞分化及骨吸收功能的影响,探讨小檗碱抑制骨吸收的细胞学基础。方法:采用原代培养的成骨细胞和骨髓单核细胞联合培养的方法,在1,25-(OH)2维生素D3和地塞米松作用下,使骨髓单核细胞分化形成破骨细胞。通过相差显微镜观察细胞形态,通过抗酒石酸酸性磷酸酶(tartrate-resistant acid phosphatase,TRAP)染色和观察骨片上骨吸收陷窝的形成鉴定破骨细胞。磷酸苯二钠法测定破骨细胞抗酒石酸酸性磷酸酶的活性,计算机图像分析技术测定骨片上破骨性骨吸收陷窝的面积。结果:小檗碱在0.1~10μmol/L范围内,浓度依赖性地抑制TRAP阳性多核破骨细胞的形成和TRAP活性,减少破骨性骨吸收陷窝的面积;在10μmol/L浓度下,对破骨细胞的抑制作用最强,对TRAP阳性多核破骨细胞的形成和TRAP活性的抑制率分别达到了60.45%和42.12%,骨吸收陷窝面积减少72.69%。结论:小檗碱通过抑制破骨细胞的形成、分化和骨吸收功能减少骨质的丢失。 Objective: To observe the effects of berberine on vitro, and to investigate the cellular mechanism of osteoclastic differentiation and bone resorption action in its inhibitory effects on bone resorption. Methods: The multinucleated osteoclasts (MNCs) dexamethasone from bone marrow cells in the coculture were derived by 1, 25-dihydroxyvitamin D3 and system with primary osteoblastic cells. The tartrateresistant acid phosphatase (TRAP) staining and image analysis of bone resorption pit on dental slices were used to identify osteoclast. The activity of TRAP was measured by p-nitrophenyl sodium phosphate assay. The bone resorption pit area on the bone slices formed by osteoclasts was measured by computer image processing. Results: At the concentrations of 0. 1, 1 and 10 μmol/L, berberine dose-dependently suppressed the formation of TRAP-positive multinucleated cells, the TRAP activity and the osteoclastic bone resorption. The strongest inhibitory effect was exhibited at the concentration of 10 μmol/L, with the inhibiting rate of 60.45%, 42.12% and 72.69% respectively. Conclusion: Berberine can decrease bone loss through inhibition of osteoclast formation, differentiation and bone resorption.
出处 《中西医结合学报》 CAS 2009年第4期342-348,共7页 Journal of Chinese Integrative Medicine
基金 国家自然科学基金重大研究计划资助项目(No.90709023)
关键词 小檗碱 骨质疏松 破骨细胞 骨吸收 berberine osteoporosis osteoclasts bone resorption
  • 相关文献

参考文献24

  • 1戴如春,张丽,廖二元.骨质疏松的诊治进展[J].中国医刊,2008,43(4):4-6. 被引量:69
  • 2Davison S, Davis SR. Hormone replacement therapy: current controversies. Clin Endocrinol (Oxf). 2003; 58 (3) : 249-261.
  • 3Hu JP, Takahashi N, Yamada T. Coptidis rhizoma inhibits growth and proteases of oral bacteria. Oral Dis. 2000; 6(5): 297-302.
  • 4Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol. 2001; 53(5): 763-768.
  • 5Hwang JM, Kuo HC, Tseng TH, Liu JY, Chu CY. Berberine induces apoptosis through a mitochondria/ caspases pathway in human hepatoma cells. Arch Toxieol. 2006, 80(2): 62-73.
  • 6Kuo CL, Chou CC, Yung BY. Berberine complexes with DNA in the berberine-indueed apoptosis in human leukemic HL-60 cells. Cancer Lett. 1995; 93(2): 193- 200.
  • 7Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces Gl-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther. 2006; 5 (2) : 296- 308.
  • 8Li H, Miyahara T, Tezuka Y, Namba T, Nemoto N, Tonami S, Seto H, Tada T, Kadota S. The effect of Kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan. Biol Pharm Bull. 1998, 21(12): 1322-1326.
  • 9Li H, Miyahara T, Tezuka Y, Namba T, Suzuki T, Dowaki R, Watanabe M, Nemoto N, Tonami S, Seto H, Kadota S. The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. Biol Pharm Bull. 1999; 22(4): 391-396.
  • 10Qin L, Han T, Zhang Q, Cao D, Nian H, Rahman K, Zheng H. Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula. J Ethnopharmacol. 2008; 118(2) : 271-279.

二级参考文献19

  • 1史敏,巴雅,杜红,秦永德.绝经后妇女尼尔雌醇治疗前后骨密度及骨代谢的变化[J].中国骨质疏松杂志,1999,5(1):46-48. 被引量:19
  • 2原发性骨质疏松症诊疗指南(讨论稿)[J].中华全科医师杂志,2006,5(8):455-457. 被引量:65
  • 3于德泉 杨峻山.分析化学手册:第7分册[M].北京:化学工业出版社,1999.838.
  • 4[1]胡熙明.中华本草:上册 [M].上海:上海科学技术出版社,1996.1026-1034.
  • 5徐晓利,生物化学工具,1980年
  • 6Kalu D N.The ovariectomized rat model of postmenopausal bone loss[J].Bone Miner,1991,15(3):175-191.
  • 7Chappard D, Retailleau-Gaborit N, Legrand E, et al. Comparison insight bone measurements by histomorphometry and mieroCT[J]. J Bone Miner Res, 2005, 20:1177 -1184.
  • 8Chesnut Ⅲ CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis[J]. J Bone Miner Res, 2004, 19:1241 - 1249.
  • 9Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [ J ]. Obstetrical and gynecological survey, 2007, 62:526-527.
  • 10Stephen L Kates, Olivia S Kates, Daniel A. Mendelson, et al Advance in the medical management of osteoporosis [ J]. Care Injured, 2007, 38s3:s17 - s23.

共引文献129

同被引文献161

引证文献14

二级引证文献114

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部